<div id="readability-page-1"><p>Cassava Sciences (NASDAQ:SAVA - Get Free Report) is expected to post its  Q4 2025 results before the market opens on Tuesday, March 3rd. Analysts expect Cassava Sciences to post earnings of ($0.30) per share for the quarter. Investors can check  the company's upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 10, 2026 at 10:30 AM ET.</p><div><p><span></span><span>Get <strong>Cassava Sciences</strong> alerts:</span></p></div><h2>Cassava Sciences Stock Down 3.0%</h2><ul><li>Analysts Believe Cassava Sciences Now Has 300% Upside From Here</li></ul><p>NASDAQ SAVA opened at $2.28 on Monday. Cassava Sciences has a 52 week low of $1.15 and a 52 week high of $4.98. The stock has a market capitalization of $110.15 million, a PE ratio of -1.04 and a beta of -0.85. The firm has a 50 day moving average of $2.12 and a two-hundred day moving average of $2.68. </p><h2>Wall Street Analysts Forecast Growth</h2><p>Several research firms have recently issued reports on SAVA. Weiss Ratings  reaffirmed a &#34;sell (e+)&#34; rating on shares of Cassava Sciences in a research report on Friday, December 26th. Wall Street Zen cut Cassava Sciences from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday. One analyst  has rated the stock with a Hold rating and one  has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of &#34;Reduce&#34; and an average target price of $2.00.</p><ul><li>Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?</li></ul><p><b>View Our Latest Research Report on Cassava Sciences</b></p><h2>Hedge Funds Weigh In On Cassava Sciences</h2><p>Several large investors have recently bought and sold shares of the stock. Jump Financial LLC acquired a new stake in shares of  Cassava Sciences in the 4th quarter valued at about $181,000.  Federated Hermes Inc. increased its position in  Cassava Sciences by 111.3% during the fourth quarter. Federated Hermes Inc. now owns 91,479 shares of the company's stock worth $181,000 after buying an additional 48,194 shares during the period.  Strs Ohio purchased a new stake in  Cassava Sciences in the first quarter valued at approximately $178,000.  OMERS ADMINISTRATION Corp purchased a new stake in  Cassava Sciences in the fourth quarter valued at approximately $166,000.  Finally, Marshall Wace LLP acquired a new stake in shares of  Cassava Sciences in the second quarter valued at approximately $130,000. Institutional investors and hedge funds own  38.05% of the company's stock. </p><h2>About Cassava Sciences</h2> (Get Free Report)<ul><li>3 small-cap biotechs with potential breakthroughs in 2024</li></ul><p>Cassava Sciences, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies and diagnostics for Alzheimer's disease and related neurodegenerative disorders. Headquartered in Austin, Texas, the company was originally founded as Pain Therapeutics in 1998 and rebranded to Cassava Sciences in 2017. Cassava's research program centers on small molecules designed to address underlying mechanisms of neurodegeneration rather than solely targeting amyloid plaques or tau tangles.  </p><p>The company's lead drug candidate, simufilam (formerly PTI-125), is a proprietary small molecule that aims to restore normal shape and function to the scaffolding protein filamin A, which has been implicated in impaired neuronal signaling and inflammation in Alzheimer's patients.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Cassava Sciences</li><li>Silver Crossed $100: Is the $500 surge next? (Join us March 4)</li><li>3 Signs You May Want to Switch Financial Advisors</li><li>ATCX is Sitting on One of Brazil’s Largest Critical Minerals Portfolios!</li><li>America’s 1776 happening again</li><li>I'm 70 With $1.5M: Would Converting $120K a Year to a Roth Be Smart or a Costly Mistake? (Ask An Advisor)</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0FWQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0FWQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Cassava Sciences Right Now?</h2><p>Before you consider Cassava Sciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cassava Sciences wasn't on the list.</p><p>While Cassava Sciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SAVA

<p>Cassava Sciences (NASDAQ:SAVA) is set to announce its Q4 2025 earnings on March 3, with analysts predicting a loss of $0.30 per share. The stock is currently down 3.0%, trading at $2.28, with a market cap of $110.15 million. Recent analyst ratings include a "sell" from Weiss Ratings and a downgrade from Wall Street Zen. Institutional investors hold 38.05% of the stock. Cassava focuses on developing therapies for Alzheimer's disease, with its lead candidate, simufilam, targeting neurodegeneration mechanisms.</p>

Cassava Sciences (SAVA) Expected to Announce Quarterly Earnings on Tuesday